Neuroprotective potential of EGF-treated bone marrow mesenchymal stromal cells in trimethyltin-induced neurodegeneration: in vitro and in vivo studies

Macromolecular Research · Springer Nature · 2026-11-10 · DOI: 10.1007/s10616-026-01109-1

Аннотация

Background: Neurodegenerative diseases are progressive, debilitating, and often life-threatening disorders of the nervous system. Bone marrow-derived mesenchymal stromal cells are considered a promising therapeutic strategy for different diseases, including neurodegeneration. EGF has been reported to promote neuron-like characteristics and neurotrophic responses in BM-MSCs. This study was conducted to assess the role of EGF-treated Bone marrow mesenchymal stromal cells in a neurodegenerative rat model (a novel approach). Methods: In vitro analysis was performed to evaluate the specific dose and cell viability using MTT and Crystal Violet assays and morphology under a microscope. For the in vivo study, forty rats were randomly allocated into four groups: Control, Injury, injury + Bone marrow mesenchymal stromal cells (BM-MSCS), and injury + EGF-treated Bone marrow mesenchymal stromal cells (BM-MSCs). A neurodegenerative rat model was developed with the use of trimethyltin chloride. Following TMT induction, BM-MSCs and EGF-treated BM-MSCs were administered via the intrathecal route. Behavioral performance, Histopathological alteration, protein expression, and gene expression were evaluated. The assessed biomarkers included TNF-α (inflammation), NFL (neuronal injury), MAPT (Tau gene expression), the neurotrophic factors BDNF and NGF, together with the progenitor-associated marker Nestin. Findings: In vitro, BM-MSCs treated with 10 ng/mL EGF maintained cell viability comparable to untreated controls, as confirmed by MTT and Crystal Violet assays, while exhibiting pronounced neuron-like morphological characteristics. In vivo, transplantation of EGF-treated BM-MSCs significantly improved spatial learning, memory, and neuromuscular performance compared with both the TMT-induced injury group and the untreated BM-MSC group. Histopathological analysis demonstrated improved preservation of hippocampal architecture following EGF-treated BM-MSC transplantation. Furthermore, EGF-treated BM-MSCs significantly reduced the expression of TNF-α, neurofilament light chain (NFL), and phosphorylated Tau (p-Tau), while significantly increasing the expression of BDNF, NGF, and Nestin at both the protein and gene levels. Overall, EGF preconditioning enhanced the neuroprotective and recovery associated effects of BM-MSCs in the TMT-induced neurodegenerative rat model. Conclusion: EGF-preconditioned BM-MSCs attenuated TMT-induced neurodegenerative changes by improving behavioral performance, reducing neuroinflammatory and neuronal injury-associated responses, preserving hippocampal cellular and tissue integrity, and enhancing neurotrophic support. These findings suggest that EGF preconditioning may potentiate the neuroprotective and immunomodulatory effects of BM-MSCs and may represent a promising strategy for the treatment of neurodegenerative disorders.

Читать у издателя →

Похожие статьи